NGM raises $51 million
This article was originally published in Scrip
Executive Summary
NGM Biopharmaceuticals has closed the first tranche of a $51 million series B financing round to further its discovery platform based on biological insights into the effects of bariatric gastric bypass surgery and post-surgical resolution of type 2 diabetes and other metabolic disorders.